Elidel and Benicar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Elidel (pimecrolimus) and Benicar (olmesartan medoxomil). Common drug interactions include injection site haemorrhage among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Elidel and Benicar. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Elidel?

Elidel has active ingredients of pimecrolimus. It is often used in eczema. eHealthMe is studying from 5,201 Elidel users. Check the latest studies of Elidel.

What is Benicar?

Benicar has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 36,002 Benicar users. Check the latest studies of Benicar.

On Jul, 09, 2026

29 people who take Elidel and Benicar together, and have interactions are studied.

What are the common drug interactions of Elidel and Benicar, by gender? *:

female:

Injection site haemorrhage (bleeding from injection site)
Injection site pain
Injection site reaction
Joint range of motion decreased (disease of joint movement)
Melanosis (a disorder of pigmentation of the wall of the colon)
Mesenteric lymphadenopathy (disease of mesenteric arteries nearby lymph nodes)
Mobility decreased (ability to move is reduced)
Muscle spasms (muscle contraction)
Muscle tightness
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)

male:

Fatigue (feeling of tiredness)
Chest discomfort
Hepatic enzyme increased
Hepatitis (inflammation of the liver)
Hyperhidrosis (abnormally increased sweating)
Influenza
Myalgia (muscle pain)
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
Nasal discomfort
Nausea (feeling of having an urge to vomit)

What are the common drug interactions of Elidel and Benicar, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Bone density decreased
Chronic kidney disease
Cough
Dyspnoea (difficult or laboured respiration)
Emotional distress
Pain
Pleural effusion (water on the lungs)

40-49:

n/a

50-59:

Emotional distress
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Gait disturbance
General physical health deterioration (weak health status)
Hyperaesthesia
Joint range of motion decreased (disease of joint movement)
Mobility decreased (ability to move is reduced)
Muscle tightness
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Oedema peripheral (superficial swelling)

60+:

Fatigue (feeling of tiredness)
Weight decreased
Gastric ulcer haemorrhage (bleeding ulcer of stomach)
Gastroenteritis (inflammation of stomach and intestine)
Hepatic cyst
Hepatic lesion
Hepatitis (inflammation of the liver)
Hypophagia (reduced food intake)
Injection site erythema (redness at injection site)
Intestinal mucosal atrophy (wasting or decrease in size of a intestinal mucosal)

What are the existing conditions these people have? *

Abdominal Pain Upper: 9 people, 31.03%
Diarrhea: 8 people, 27.59%
High Blood Cholesterol: 7 people, 24.14%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 4 people, 13.79%
Sinusitis (inflammation of sinus): 3 people, 10.34%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 6.90%
Asthma: 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Elidel and Benicar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously